203 related articles for article (PubMed ID: 28302100)
21. Aprepitant for refractory nivolumab-induced pruritus.
Ito J; Fujimoto D; Nakamura A; Nagano T; Uehara K; Imai Y; Tomii K
Lung Cancer; 2017 Jul; 109():58-61. PubMed ID: 28577951
[TBL] [Abstract][Full Text] [Related]
22. Gastroparesis-associated refractory nausea treated with aprepitant.
Fahler J; Wall GC; Leman BI
Ann Pharmacother; 2012 Dec; 46(12):e38. PubMed ID: 23191934
[TBL] [Abstract][Full Text] [Related]
23. More on aprepitant for erlotinib-induced pruritus.
Gerber PA; Buhren BA; Homey B
N Engl J Med; 2011 Feb; 364(5):486-7. PubMed ID: 21288112
[No Abstract] [Full Text] [Related]
24. Itch Management: Treatments under Development.
Pereira MP; Ständer S
Curr Probl Dermatol; 2016; 50():71-6. PubMed ID: 27578074
[TBL] [Abstract][Full Text] [Related]
25. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone.
Oechsle K; Müller MR; Hartmann JT; Kanz L; Bokemeyer C
Onkologie; 2006 Dec; 29(12):557-61. PubMed ID: 17202825
[TBL] [Abstract][Full Text] [Related]
26. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
27. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
Prommer E
J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
[TBL] [Abstract][Full Text] [Related]
28. Does continuous subcutaneous infusion of lignocaine relieve intractable pruritus associated with advanced cutaneous T-cell lymphoma? A retrospective case series review.
Norris J; Barker J; Buelens O; Spruijt O
Palliat Med; 2019 May; 33(5):552-556. PubMed ID: 30712496
[TBL] [Abstract][Full Text] [Related]
29. Aprepitant for antiemesis after laparoscopic gynaecological surgery: A randomised controlled trial.
Ham SY; Shim YH; Kim EH; Son MJ; Park WS; Lee JS
Eur J Anaesthesiol; 2016 Feb; 33(2):90-5. PubMed ID: 26694939
[TBL] [Abstract][Full Text] [Related]
30. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
31. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.
Keller M; Montgomery S; Ball W; Morrison M; Snavely D; Liu G; Hargreaves R; Hietala J; Lines C; Beebe K; Reines S
Biol Psychiatry; 2006 Feb; 59(3):216-23. PubMed ID: 16248986
[TBL] [Abstract][Full Text] [Related]
32. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial.
Kang HJ; Loftus S; Taylor A; DiCristina C; Green S; Zwaan CM
Lancet Oncol; 2015 Apr; 16(4):385-94. PubMed ID: 25770814
[TBL] [Abstract][Full Text] [Related]
33. What's New in Cutaneous T-Cell Lymphoma-Associated Pruritus.
Biazus Soares G; Guitart J; Yosipovitch G
Am J Clin Dermatol; 2024 Jan; 25(1):67-77. PubMed ID: 37971624
[TBL] [Abstract][Full Text] [Related]
34. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
35. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin.
Kim YH; Demierre MF; Kim EJ; Lerner A; Rook AH; Duvic M; Robak T; Samtsov A; McCulloch W; Chen SC; Waksman J; Nichols J; Whittaker S
Leuk Lymphoma; 2013 Feb; 54(2):284-9. PubMed ID: 22839723
[TBL] [Abstract][Full Text] [Related]
36. Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting.
Svanberg A; Birgegård G
Oncology; 2015; 89(1):31-6. PubMed ID: 25659986
[TBL] [Abstract][Full Text] [Related]
37. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
38. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.
Manak MM; Moshkoff DA; Nguyen LT; Meshki J; Tebas P; Tuluc F; Douglas SD
AIDS; 2010 Nov; 24(18):2789-96. PubMed ID: 20975512
[TBL] [Abstract][Full Text] [Related]
39. Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat.
Meyer N; Paul C; Misery L
Acta Derm Venereol; 2010; 90(1):12-7. PubMed ID: 20107719
[TBL] [Abstract][Full Text] [Related]
40. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.
Cedeno-Laurent F; Singer EM; Wysocka M; Benoit BM; Vittorio CC; Kim EJ; Yosipovitch G; Rook AH
Clin Immunol; 2015 May; 158(1):1-7. PubMed ID: 25762519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
